Brain CHIP: removing the culprits in neurodegenerative disease

Trends in Molecular Medicine

Volumn 13, Issue 1, 2007, Pages 32-38

  Dickey, Chad A ^a   Patterson, Cam ^b   Dickson, Dennis ^c   Petrucelli, Leonard ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL HSC70 INTERACTING PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN 70; UNCLASSIFIED DRUG;

ADAPTATION; AGING; ALZHEIMER DISEASE; CATALYSIS; CATALYST; CELL FUNCTION; DEGENERATIVE DISEASE; HUMAN; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STRESS; UBIQUITINATION;

AGE FACTORS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; PROTEIN TRANSPORT; UBIQUITIN-PROTEIN LIGASES;

EID: 33845874433     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.11.003     Document Type: Review

References (69)

1. Morley J.F., and Morimoto R.I. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell 15 (2004) 657-664
2. Hsu A.L., et al. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300 (2003) 1142-1145
3. Howland D.S., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1604-1609
4. Krobitsch S., and Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1589-1594
5. Qin Z.H., et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci. 24 (2004) 269-281
6. Cantuti-Castelvetri I., et al. Alpha-synuclein and chaperones in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 64 (2005) 1058-1066
7. Shimura H., et al. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 279 (2004) 4869-4876
8. Petrucelli L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 (2004) 703-714
9. Kamal A., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 (2003) 407-410
10. Chang H.C., et al. In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol. Cell. Biol. 17 (1997) 318-325
11. Frydman J., and Hohfeld J. Chaperones get in touch: the Hip-Hop connection. Trends Biochem. Sci. 22 (1997) 87-92
12. Chen S., and Smith D.F. Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J. Biol. Chem. 273 (1998) 35194-35200
13. Johnson B.D., et al. Hop modulates Hsp70/Hsp90 interactions in protein folding. J. Biol. Chem. 273 (1998) 3679-3686
14. Ballinger C.A., et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19 (1999) 4535-4545
15. Connell P., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3 (2001) 93-96
16. MacLean M., and Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 8 (2003) 114-119
17. Qian S.B., et al. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440 (2006) 551-555
18. Dai Q., et al. Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. J. Biol. Chem. 280 (2005) 38673-38681
19. Zhang B., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 227-231
20. Dai Q., et al. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 22 (2003) 5446-5458
21. Beere H.M., and Green D.R. Stress management - heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol. 11 (2001) 6-10
22. Esser C., et al. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280 (2005) 27443-27448
23. Bonvini P., et al. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 64 (2004) 3256-3264
24. Xu W., et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12847-12852
25. Morimoto R.I., and Santoro M.G. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat. Biotechnol. 16 (1998) 833-838
26. Strahler J.R., et al. Diminished phosphorylation of a heat shock protein (HSP 27) in infant acute lymphoblastic leukemia. Biochem. Biophys. Res. Commun. 175 (1991) 134-142
27. Efferth T., et al. Differential expression of the heat shock protein 70 in the histological compartments of nephroblastomas. Anticancer Res. 21 4B (2001) 2915-2920
28. Sawa A., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5 (1999) 1194-1198
29. Arenas J., et al. Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol. 43 (1998) 397-400
30. Squitieri F., et al. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?. Mech. Ageing Dev. 127 (2006) 208-212
31. La Spada A.R., et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352 (1991) 77-79
32. Gatchel J.R., and Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6 (2005) 743-755
33. Cummings C.J., et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19 (1998) 148-154
34. McGowan D.P., et al. Amyloid-like inclusions in Huntington's disease. Neuroscience 100 (2000) 677-680
35. Kim W.Y., et al. Evidence for sequestration of polyglutamine inclusions by Drosophila myeloid leukemia factor. Mol. Cell. Neurosci. 29 (2005) 536-544
36. Kobayashi Y., et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275 (2000) 8772-8778
37. Muchowski P.J., et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7841-7846
38. Jana N.R., et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280 (2005) 11635-11640
39. Miller V.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 25 (2005) 9152-9161
40. Al-Ramahi I., et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281 (2006) 26714-26724
41. He B., et al. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J. Biol. Chem. 279 (2004) 30643-30653
42. Rees I., et al. The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner. Biochim. Biophys. Acta 1764 (2006) 1073-1079
43. Maraganore D.M., et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55 (2004) 512-521
44. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
45. Bonifati V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
46. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
47. Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18676-18681
48. Lee H.J., and Lee S.J. Characterization of cytoplasmic α-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277 (2002) 48976-48983
49. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
50. Kruger R., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
51. Singleton A.B., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
52. Klucken J., et al. Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies. Acta Neuropathol. (Berl.) 111 (2006) 101-108
53. Shin Y., et al. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280 (2005) 23727-23734
54. Imai Y., et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell 10 (2002) 55-67
55. Moore D.J., et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14 (2005) 71-84
56. Oddo S., et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
57. Feany M.B., and Dickson D.W. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. 40 (1996) 139-148
58. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
59. Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4913-4917
60. Ihara Y., et al. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. (Tokyo) 99 (1986) 1807-1810
61. Weaver C.L., et al. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging 21 (2000) 719-727
62. Guillozet-Bongaarts A.L., et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26 (2005) 1015-1022
63. Pickering-Brown S., et al. Pick's disease is associated with mutations in the tau gene. Ann. Neurol. 48 (2000) 859-867
64. Grelle G., et al. Identification of VCP/p97, carboxyl terminus of Hsp70-interacting protein (CHIP), and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol. Cell. Proteomics 5 (2006) 234-244
65. Cripps D., et al. Alzheimer's-disease-specific conformation of hyperphosphorylated phf-tau is polyubiquitinated through lys-48, lys-11, and lys-6 ubiquitin conjugation. J. Biol. Chem. 281 (2006) 10825-10838
66. Dickey C.A., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 26 (2006) 6985-6996
67. Lindsten K., et al. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21 (2003) 897-902
68. Liu A.Y., et al. Attenuated heat shock transcriptional response in aging: molecular mechanism and implication in the biology of aging. EXS 77 (1996) 393-408
69. Cohen E., et al. Opposing activities protect against age-onset proteotoxicity. Science 313 (2006) 1604-1610